

**REMARKS**

At the outset, the Examiner is thanked for the thorough review and consideration of the pending application. The Office Action dated November 29, 2007 has been received and its contents carefully reviewed.

Claims 7, 21-22, 24-27, and 31 are hereby amended to clarify the language of the claims and not to overcome prior art. Also, the specification has been amended to insert priority data. Accordingly, claims 1-35 are currently pending. Reexamination and reconsideration of the pending claims is respectfully requested.

The Office Action objects to claims 7, 27, and 31 based on minor informalities. The claims have been amended to obviate the objection.

The Office Action rejects claims 21-26 under 35 U.S.C. §112, second paragraph as being indefinite. Claims 21-22 and 24-26 have been amended to obviate the rejection.

The Office Action rejects claims 1-6, 8-18 and 20-35 under 35 U.S.C. §103(a) as being obvious over KR2001060776 to Han ("*Han*") in view of KR2004045115 to Cho ("*Cho*"). The rejection is respectfully traversed.

The Office Action recognizes the deficiencies of *Han* in rejecting independent claims 1-5. However, the Office Action alleges that *Cho* cures the deficiencies of *Han*.

*Cho* may not be used as prior art against the present application. *Cho* has a publication date of June 1, 2004. The present application is a national stage application of a PCT application with an international filing date of March 12, 2004. Therefore, the present application has a filing date that predates the publication date of *Cho*.

The Office Action rejects claim 7 under 35 U.S.C. §103(a) as being obvious over *Han* and *Cho*, and further in view of KR20010093969 to Kim ("*Kim*"). The rejection is respectfully traversed.

Amdt. dated Proposed

Reply to Office Action dated November 29, 2007

*Kim* does not cure the deficiencies of *Han* and *Cho*, and therefore the combination does not render obvious the features of claim 1. Claim 7 is at least allowable by virtue of its dependency from claim 1.

The Office Action rejects claim 19 under 35 U.S.C. §103(a) as being obvious over *Han* and *Cho*, and further in view of JP 2002346288 to Iwai ("*Iwai*"). The rejection is respectfully traversed.

*Iwai* does not cure the deficiencies of *Han* and *Cho*, and therefore the combination does not render obvious the features of claim 1. Claim 19 is at least allowable by virtue of its dependency from claim 1.

The foregoing amendments place the application in condition for allowance and early, favorable action is respectfully solicited.

If for any reason the Examiner finds the application other than in condition for allowance, the Examiner is requested to call the undersigned attorney at (202) 496-7500 to discuss the steps necessary for placing the application in condition for allowance. All correspondence should continue to be sent to the below-listed address.

If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time, or any other fees required to complete the filing of this response, may be charged to Deposit Account No. 50-0911. Please credit any overpayment to deposit Account No. 50-0911. A duplicate copy of this sheet is enclosed.

Dated: **February 29, 2008**

Respectfully submitted,

By

  
**Mark R. Kresloff**

Registration No.: 42,766

McKENNA LONG & ALDRIDGE LLP

1900 K Street, N.W.

Washington, DC 20006

(202) 496-7500

Attorneys for Applicant